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Introduction. The current chemotherapy for Chagas disease is unsatisfactory with only two 
drugs available for treatment. Research to discover new drugs for Chagas disease is urgent. 
Hexadecyl-phosphocholine (HPC, miltefosine) has been demonstrated to have in vitro activity 
against Trypanosoma cruzi parasites, but its activity on different Colombian T. cruzi strains is not 
known.
Objective. To evaluate the in vitro susceptibility of T. cruzi strains isolated from humans and 
vectors in Santander, Colombia. to miltefosine, nifurtimox and benznidazole. 
Materials and methods. Eight T. cruzi Colombian strains and three reference strains (Esmeraldo, 
SilvioX10 and Y) were studied. Drug activities against extracellular epimastigotes and intracellular 
amastigotes were determined by microscopic counting. The results were expressed as the 
concentrations that inhibited 50% and 90% growth (IC50 and IC90).
Results. For miltefosine a similar range of drug activity was observed against all the Colombian 
strains, all parasites being more susceptible to miltefosine than to the reference drugs. The 
intracellular amastigotes were more susceptible to miltefosine (IC50 0.08 to 0.63 µM and IC90 
0.21 to 2.21 µM) than extracellular forms (IC50 <0.92 to 2.29 µM and IC90 1.38 to 4.76 µM). For 
reference drugs, parasites were more susceptible to nifurtimox than to benznidazole and some 
differences in activity of benznidazole between T. cruzi strains was observed.
Conclusions. The results showed the significant in vitro activity of miltefosine against T. cruzi 
stages, and the expected results for the reference drugs. Further in vivo studies with miltefosine 
are planned.
Key words: Trypanosoma cruzi, Chagas disease, miltefosine, benznidazole, nifurtimox, drug 
therapy, Colombia.
Susceptibilidad in vitro a hexadecilfosfocolina (miltefosina), nifurtimox y benznidazole de 
cepas de Trypanosoma cruzi aisladas en Santander, Colombia
Introducción. Los tratamientos actuales para la enfermedad de Chagas son insatisfactorios y sólo 
existen dos medicamentos disponibles. La búsqueda de alternativas terapéuticas es prioritaria. 
La hexadecilfosfocolina (miltefosina) ha mostrado actividad in vitro contra Trypanosoma cruzi. 
Sin embargo, su actividad en aislamientos de T. cruzi obtenidos en Colombia aún no ha sido 
reportada.
Objetivo. Evaluar la susceptibilidad in vitro a miltefosina, nifurtimox y benznidazole de cepas de 
T. cruzi aisladas de humanos y vectores en Santander, Colombia.
Materiales y métodos. Se evaluó la susceptibilidad de los tres medicamentos en ocho cepas 
colombianas de T. cruzi y tres cepas de referencia: Esmeraldo, Silvio X10 y Y. La actividad de 
los compuestos fue determinada en epimastigotes extracelulares y amastigotes intracelulares, 
por conteo microscópico. Los resultados se expresaron en concentraciones inhibitorias 50 y 90 
(CI50 y CI90).
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Resultados. Para la miltefosina, se observaron rangos similares en la actividad del medicamento 
entre las cepas colombianas; todos los parásitos fueron más susceptibles a la miltefosina que 
a los medicamentos de referencia. Los amastigotes intracelulares fueron más sensibles a la 
miltefosina (CI50, 0,08 a 0,63 µM y CI90, 0,21 a 2,21 µM) que las formas extracelulares (CI50, <0,92 
a 2,29 µM y CI90, 1,38 a 4,76 µM). En los medicamentos de referencia, los parásitos fueron más 
susceptibles al nifurtimox que al benznidazole. Se observaron algunas diferencias en la actividad 
del benznidazole en las cepas estudiadas de T. cruzi. 
Conclusiones. Los resultados obtenidos de la actividad in vitro de miltefosina y de los 
medicamentos de referencia contra aislamientos de T. cruzi son satisfactorios y serán 
considerados en estudios posteriores in vivo.
Palabras clave: Trypanosoma cruzi, enfermedad de Chagas, miltefosina, benznidazol, nifurtimox, 
quimioterapia, Colombia.
Chagas disease, caused by the protozoan 
parasite Trypanosoma cruzi (Kinetoplastida: 
Trypanosomatidae), constitutes one of the largest 
parasitic disease burdens in Latin America 
where approximately 13-15 million of people 
are affected (1). Trypanosoma cruzi strains 
are divided into two main well-defined groups 
called T. cruzi I and T. cruzi II; five subgroups 
have been identified inside the T. cruzi II group 
(IIa, IIb, IIc, IId and IIe) (2). In Colombia, 5% 
of the population is infected in endemic areas 
and the predominance of T. cruzi I has been 
reported (3-7). The Santander Province is one 
of the territorial divisions where the prevalence 
of infection is highest (8,9). No vaccines are 
available, and the chemotherapy remains 
precarious with only two available drugs, the 
nitrofuran derivative, nifurtimox (Lampit, Bayer) 
and 2-nitroimidazole benznidazole (Radanil, 
Roche). Both are restricted mainly to the 
treatment of the acute phase or the congenital 
infection (10,11). Currently, these drugs have 
severe limitations, including high frequency 
of undesirable side effects, long protocols of 
treatment, and limited efficacy and availability 
(12,13). The research to discover new drugs for 
the treatment of Chagas disease is imperative.
Hexadecylphosphocholine (HPC; miltefosine), 
an alkylphosphocholine developed initially as an 
anticancer drug, constitutes the first oral treat-
ment for visceral and cutaneous leishmaniasis 
(14,15). It shows a broad spectrum of drug 
activity on several types of parasites such as 
Leishmania spp., T. cruzi and Entamoeba 
histolytica (16). In T. cruzi models, it is active 
against free and intracellular live forms of 
parasites as well as strains with different levels 
of susceptibility to benznidazole (17,18). Its 
mechanism of action is not clear, but parasite 
membranes are probably the primary target, 
possibly by interference with lipid metabolism 
(18,19). Additionally, synergism of miltefosine or 
edelfosine (another alkyl-phospholipid drug) in 
combination with ketoconazole has also been 
demonstrated (18-20).
The purpose of the current study was to evaluate 
the in vitro activities of miltefosine, nifurtimox and 
benznidazole against Colombian T. cruzi strains, 
as well as against the Silvio X10, Esmeraldo and 
Y reference strains.
Materials and methods
Parasites
Eight strains of T. cruzi, isolated from various 
hosts by hemoculture and xenoculture, were 
used (Luna KP, Jaramillo CL, Gutierrez R, 
Esteban L, Angulo VM. Aislamiento de T. cruzi en 
pacientes en fase crónica de la enfermedad de 
Chagas por medio de hemocultivo y xenocultivo. 
Biomédica. 2003;23 (Supl.1):119). They have 
been previously characterized by amplification 
of the mini-exon gene nontranscribed spacer 
(Gutierrez R, Luna KP, Angulo VM, Fernandes 
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Chagas. Biomédica. 2003;23 (Supl.1):119-20). 
Parasites originated from the domestic cycle in 
the biogeographical area of Santander, Colombia 
(Table 1). In addition, T. cruzi reference strains 
Silvio X10 (T. cruzi I) Esmeraldo and Y (T. cruzi 
II) were used. The parasites were maintained 
by serial passage in Liver Infusion Tryptose 
(LIT) medium supplemented with 10% heat 
inactivated fetal calf serum (hiFCS, Gibco, USA) 
and hemin (10 mg/L, Sigma) at 28 °C. They were 
used within four passages of isolation.
Drugs
Hexadecylphosphocholine (HPC, miltefosine) 
was obtained from A.G Scientific, INC, nifurtimox 
from Bayer (Germany) and benznidazole from 
Roche (Switzerland). Nifurtimox and  benznida-
zole were dissolved in dimethyl sulfoxide (DMSO). 
The final DMSO concentration did not exceed 1% 
(v/v). Miltefosine was dissolved directly in culture 
medium. Working solutions were prepared in LIT 
or RPMI 1640 culture media immediately before 
the assays.
Epimastigotes assay
Parasites were harvested during the exponential 
growth phase, diluted in LIT to 5x105 parasites/
mL and incubated in a three-fold dilution series 
of miltefosine (0.92-25.0 µM), nifurtimox (1.1-
261 µM) and benznidazole (1.2-288 µM) in 96 
well multiwell plates (Becton Dickinson, New 
Jersey, USA), for 72 h at 28 °C. Each drug 
Table 1. Trypanosoma cruzi parasites strains used in this 
study.
Parasite strains Classificationa Host
215 Z3 Human
209 T. cruzi I Human
204 T. cruzi I Human
132 T. cruzi I Human
070I06 T. cruzi I Rhodnius prolixus
320I01 T. cruzi I R. prolixus
421I02 T. cruzi I Triatoma dimidiata
187401 T. cruzi I T. dimidiata
Silvio X10 T. cruzi I Human
Esmeraldo T. cruzi II Human
Y T. cruzi II Human
a Classification from amplification of mini-exon gene non-
transcribed spacer by Fernández, et al., 2001 (Gutiérrez, et 
al., 2003)
concentration was evaluated in triplicate and 
control cultures were maintained without drug. 
Parasite inhibition was determined microscopic-
ally by counting parasite numbers in a Neubauer 
haemocytometer. 
Intracellular amastigotes assay
Vero cells, diluted to 3 x 105 cells/mL in RPMI 
1640 medium plus 10% hiFCS, were plated in 
16-well Lab-tekTM tissue culture chamber slides 
(Life Technologies, Paisley,UK) and allowed 
to adhere for 24 h at 37 °C in a 5% CO2-95% 
air mixture. Adherent cells were infected with 
tissue derived trypomastigotes (TDT) at a ratio 
of parasites to cells of 10:1. The cultures were 
maintained in a 5% CO2-95% air mixture at 
37 °C. TDT were obtained by successive serial 
infections in Vero cells with released parasites 
from culture supernatants. Reference strains and 
the 215 strain were not tested in the amastigote 
assay due to a failure to generate sufficient TDT 
to infect cells. After 24 h, free parasites were 
removed by washing and infected cultures were 
incubated for 72 h with three fold dilution series 
of miltefosine (0.04 to 3.30 µM), nifurtimox (0.3-
87.0 µM) and benznidazole (1.2 to 96.0 µM) for 
72 h at 37 °C, in a 5% CO2-95% air mixture. 
The cultures were then fixed with methanol and 
stained with Giemsa. Each drug concentration 
was evaluated in quadruplicate and control 
cultures were maintained without drug. Drug 
activity was determined by the percentage of 
infected cells in treated and untreated cultures. 
Statistical analyses 
The drug activities were expressed as the drug 
concentration needed to inhibit to 50% or 90% 
of parasite growth (IC50 and IC90). They were 
calculated by sigmoidal regression analysis 
(MsxlfitTM; ID Business Solution, Guildford, UK). 
Results were expressed as mean ± standard 
deviation (SD) and statistical significance was 
determined by Student t test. Values of p <0.05 
were considered significant. Each experiment 
was repeated twice.
Results
The activities of miltefosine, nifurtimox, and 
benznidazole against T. cruzi epimastigotes are 
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shown in table 2. All Colombian T. cruzi strains 
were more susceptible to miltefosine (IC50 <0.92 
to 2.29 ± 1.08 µM and IC90 1.38 ± 0.08 to 4.76 ± 
1.54 µM) and nifurtimox (IC50 2.25 ± 0.34 to 5.05 
± 1.70 µM and IC90 12.80 ± 1.24 to 26.38 ± 2.09 
µM) than to benznidazole (IC50 9.34 ± 0.78 to 
27.30 ± 1.81 µM and IC90 60.00 ± 29.05 to >288 
µM). Reference strains showed considerable 
variation in drug sensitivity: Esmeraldo was the 
least susceptible to miltefosine (IC50 3.92 ± 0.51 
µM and IC90 7.13 ± 0.70 µM) and Y was the least 
susceptible to benznidazole (IC50 20.35 ± 3.04 µM 
and IC90 >288 µM). The results were reproducible 
in the two independent experiments.
The activity range of miltefosine, nifurtimox 
and benznidazole against T. cruzi intracellular 
amastigotes is shown in table 3. All T. cruzi strains 
were highly susceptible to miltefosine (IC50 0.082 
± 0.01 to 0.63 ± 0.13 µM and IC90 0.21 ± 0.70 
to 2.21 ± 0.07 µM). Nifurtimox and benznidazole 
were also active against intracellular amastigotes 
but with lower values than miltefosine.
Variation in the activity of miltefosine against 
each life cycle stage was observed. Intracellular 
amastigotes were more sensitive than 
epimastigotes (p=0.0000) (tables 2 and 3). 
Additionally, comparisons of values of IC50 and 
Figure 1. Susceptibility of T. cruzi I and T. cruzi II 
epimastigotes to miltefosine, nifurtimox and benznidazole.
MTF: miltefosine; NIF: nifurtimox, BENZ: benznidazole, IC50 
and IC90: drug concentration to inhibit 50 or 90 percent of 
epimastigotes. The each bar represents the mean ± SD 
obtained from triplicate wells of a representative experiment. 
Values of p for each case were: IC50: MTF (p=0.68) 
NIF (p= 1.00) BENZ (p= 0.09) and IC90 MTF (p=0.46) 
BENZ (0.1989) NIF (p=0.0001). p <0.05 were considered 
statistically significant. 
IC90 between genetic groups (T. cruzi I and T. 
cruzi II) showed no significant difference, with one 
except for nifurtimox which showed significant 
differences in IC90 values (p=0.0001) (figure 1).
Table 2. In vitro activities of miltefosine, nifurtimox and benznidazole against extracellular epimastigotes of Trypanosoma 
cruzi parasites.
 µM ± SD
Parasite Miltefosine Nifurtimox Benznidazole
code IC50 IC90 IC50 IC90 IC50 IC90
215 1.17±0.04 2.06±0.14 <3.2 26.38±2.09 27.30±1.81 >288
209 1.75±0.19 3.60±0.27 5.05±1.71 16.06±2.94 21.03±3.55 >288
204 0.93±0.01 2.36±0.05 4.24±0.32 17.56±1.85 20.39±1.22 >288
132 0.96±0.04 2.36±0.16 3.81±1.91 15.11±2.47 11.65±4.15 114.46±29.76
070I06 <0.92 1.38±0.08 2.25±0.34 21.60±2.04 11.40±0.43 66.70±11.51
320I01 2.29±1.08 4.22±1.29 2.47±0.50 18.76±7.67 9.48±2.31 60.00±29.05
421I02 1.96±0.67 4.76±1.54 3.80±1.22 12.80±1.24 11.34±3.31 >288
1874-01 1.97±0.09 4.61±0.38 2.31±0.27 14.39±1.08 9.34±0.78 61.48±5.92
SilvioX10 1.85±0.28 3.82±0.48 1.56±0.40 10.58±0.71 7.33±1.53 27.39±3.72
Esmeraldo 3.92±0.51 7.13±0.70 <3.2 38.84±7.50 12.12±0.49 277.91±43.12
Y 1.73±0.16 3.50±0.26 3.50±0.58 35.28±9.47 20.35±3.04 >288
IC50 and IC90: drug concentration to inhibit 50 or 90 percent of epimastigotes growth. Data are displayed as mean ± SD of 
two independent experiments performed in triplicate. Miltefosine was more effective against epimastigotes of T. cruzi than 
nifurtimox (p=0.004) and benznidazole (p<0.001).
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Table 3. In vitro activities of miltefosine, nifurtimox and benznidazole against intracellular amastigotes of Trypanosoma cruzi 
parasites infecting Vero cells. 
 µM ±SD
Parasite Miltefosine Nifurtimox Benznidazole
code No. Exp % inf IC50 IC90 IC50 IC90 IC50 IC90
209 1 43.6 0.16±0.005 0.44±0.06 >1.1 7.35±4.52 3.66±0.10 23.09±5.94
 2 43.9 0.22±0.07 0.45±0.08 1.31±0.37 6.82±4.04 5.90±0.81 23.72±16.73
204 1 66.8 0.213±0.04 0.98±0.22 1.80±0.48 9.63±7.15 8.16±1.77 46.46±23.64
 2 66.5 0.22±0.003 0.72±0.09 1.43±0.26 5.03±2.95 6.32±1.38 74.14±15.14
132 1 47.3 0.10±0.006 0.34±0.13 1.82±0.35 6.63±1.91 5.98±0.76 25.37±8.58
 2 66.5 0.34±0.08 2.12±0.11 1.52±0.43 8.94±5.02 11.49±3.26 66.92±21.68
070I06 1 97.9 0.63±0.13 0.91±0.07 2.62±0.48 9.98±3.67 7.72±1.47 58.60±13.60
 2 89.7 0.082±0.01 0.21±0.07 1.45±0.28 5.17±3.12 5.73±1.10 38.61±17.40
320I01 1 45 0.09±0.02 1.31±0.16 ND ND 5.93±1.43 >96
 2 70 0.21±0.003 0.43±0.05 3.44±0.43 11.37±1.50 6.16±1.14 29.18±14.55
421I02 1 38.8 0.33±0.03 0.51±0.19 1.63±0.51 44.83±12.30 3.33±0.424 30.69±1.98
 2 69.6 0.13±0.03 1.99±0.87 3.23±1.72 >87 13.38±5.21 >96
187401 I 1 72.7 0.44±0.08 1.56±0.80 3.55±2.05 22.90±8.71 22.03±8.07 >96
 2 78.4 0.13±0.03 1.00±0.43 0.47±0.24 28.34±4.23 6.81±3.70 14.00±8.80
Y*  ND 0.7 ± 0.2  ND 2.7 ND ND ND
% inf: percent of infection before drug treatment; No. Exp: number of experiment; IC50 and IC90: drug concentration to inhibit 
50 or 90 percent of parasite growth; ND: not determined. *Croft S, et al. 1996 (24). 
Data are displayed as mean ± SD, as obtained from quadruplicate wells. Miltefosine was more effective against intracellular 
amastigotes of T. cruzi than nifurtimox (p= 0.0003) and benznidazole (p<0.0001)
Discussion
Differences in the drug susceptibility of T. cruzi 
strains according to genetic group, host and 
geographical origin have been described (21-23). 
However, investigations performed to date have 
mainly evaluated susceptibilities to benznidazole 
and nifurtimox. Both of these standard drugs 
have limited efficacy in the chronic form of 
Chagas disease and they produce toxic side 
effects (12). Therefore, there is an urgent need 
for studies that evaluate the activity of new anti-
trypanosomal drugs. 
This is the first study that shows the in vitro 
susceptibility to miltefosine of T.cruzi strains 
isolated from humans and vectors in a Colombian 
endemic area. All the parasites strains and stages 
tested were highly susceptible to miltefosine. 
Similar results were obtained by other authors 
using T. cruzi reference strains confirming the 
broad activity of this drug (17-19,24). Miltefosine 
was significantly more active against intracellular 
amastigotes than epimastigotes (p<0.001) (table 
3).  This has been demonstrated in earlier studies 
as well (17,19). Initially, phospholipid-derived 
drugs were discovered as a new class of 
biological response modifiers, with therapeutic 
activity in cancer mediated by an increase in the 
cytotoxic properties of macrophages (25).
Saraiva et al. (2002) observed that miltefosine 
may activate macrophages in vitro and the 
antiparasitic activity of this compound on intra-
cellular amastigotes was independent of nitric 
oxide production (17). The participation of some 
cytokines was suggested. However, the host cell 
mechanisms involved in the inhibition or parasite 
killing after miltefosine treatment is still unclear. 
Against Leishmania parasites, a significant 
variation of the in vitro susceptibility to miltefosine 
has been described for several species of 
Leishmania (26). In patients with cutaneous 
leishmaniasis, it is more effective in lesions 
caused by L. panamensis as compared to those 
by L. braziliensis (27). In contrast with the results 
obtained in the present study, miltefosine was 
found to be more active against promastigotes 
of Leishmania than against intracellular 
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Table 3. In vitro activities of miltefosine, nifurtimox and benznidazole against intracellular amastigotes of Trypanosoma cruzi 
parasites infecting Vero cells. 
 µM ±SD
Parasite Miltefosine Nifurtimox Benznidazole
code No. Exp % inf IC50 IC90 IC50 IC90 IC50 IC90
209 1 43.6 0.16±0.005 0.44±0.06 >1.1 7.35±4.52 3.66±0.10 23.09±5.94
 2 43.9 0.22±0.07 0.45±0.08 1.31±0.37 6.82±4.04 5.90±0.81 23.72±16.73
204 1 66.8 0.213±0.04 0.98±0.22 1.80±0.48 9.63±7.15 8.16±1.77 46.46±23.64
 2 66.5 0.22±0.003 0.72±0.09 1.43±0.26 5.03±2.95 6.32±1.38 74.14±15.14
132 1 47.3 0.10±0.006 0.34±0.13 1.82±0.35 6.63±1.91 5.98±0.76 25.37±8.58
 2 66.5 0.34±0.08 2.12±0.11 1.52±0.43 8.94±5.02 11.49±3.26 66.92±21.68
070I06 1 97.9 0.63±0.13 0.91±0.07 2.62±0.48 9.98±3.67 7.72±1.47 58.60±13.60
 2 89.7 0.082±0.01 0.21±0.07 1.45±0.28 5.17±3.12 5.73±1.10 38.61±17.40
320I01 1 45 0.09±0.02 1.31±0.16 ND ND 5.93±1.43 >96
 2 70 0.21±0.003 0.43±0.05 3.44±0.43 11.37±1.50 6.16±1.14 29.18±14.55
421I02 1 38.8 0.33±0.03 0.51±0.19 1.63±0.51 44.83±12.30 3.33±0.424 30.69±1.98
 2 69.6 0.13±0.03 1.99±0.87 3.23±1.72 >87 13.38±5.21 >96
187401 I 1 72.7 0.44±0.08 1.56±0.80 3.55±2.05 22.90±8.71 22.03±8.07 >96
 2 78.4 0.13±0.03 1.00±0.43 0.47±0.24 28.34±4.23 6.81±3.70 14.00±8.80
Y*  ND 0.7 ± 0.2  ND 2.7 ND ND ND
% inf: percent of infection before drug treatment; No. Exp: number of experiment; IC50 and IC90: drug concentration to inhibit 
50 or 90 percent of parasite growth; ND: not determined. *Croft S, et al. 1996 (24). 
Data are displayed as mean ± SD, as obtained from quadruplicate wells. Miltefosine was more effective against intracellular 
amastigotes of T. cruzi than nifurtimox (p= 0.0003) and benznidazole (p<0.0001)
amastigotes infecting bone marrow derived 
macrophages (26).This difference with T. cruzi 
may be due to intrinsic differences of both 
parasites. However, Croft (2003) proposed that 
in comparative studies between extracellular 
and intracellular stages one must consider that: 
(i) the effective drug concentration in host cells 
may be higher or lower than that outside the 
cells, (ii) the division rates of the stages differ, or 
(iii) the assay temperatures may differ (16). 
In experimental in vivo models, miltefosine has 
also proved to be active against Leishmania 
and T. cruzi when it was administered orally 
(17,21,28,29). Unfortunately, only two studies 
with T. cruzi have been reported; both showed 
a suppressive effect against T. cruzi on BALB/
c-infected mice, although they used different 
protocols of treatment and infection (17,21). 
Further research in a murine or another more 
appropriate in vivo model is necessary to 
determine aspects such as pharmacokinetic 
properties, dose-response relationship and 
protocols of treatment. 
We also investigated the susceptibility of T. 
cruzi strains to two nitroheterocyclic compounds 
(nifurtimox and benznidazole). Although all 
strains were susceptible to both drugs, we 
noted that nifurtimox was more active than 
benznidazole both in epimastigotes (p<0.001) 
and intracellular amastigotes (P=0.0004). Benzni-
dazole showed greater variation in its activity 
against different Colombian T. cruzi strains. This 
could be related to the different mechanisms 
of action of both drugs (30,31). Additionally, in 
contrast to the results obtained with miltefosine, 
the epimastigotes of strains isolated from vectors 
were more susceptible to nifurtimox (p=0.03) 
and benznidazole (p= 0.01) than those isolated 
from humans (table 2). Several studies have 
reported a wide variation in the susceptibility 
of a large number of T. cruzi strains isolated 
from different hosts and geographic areas to 
these nitroheterocyclic compounds (22,23,32-
34). The existence of predominant strains with 
particular levels of susceptibility to these drugs 
in specific geographical areas has been also 
reported (22,23). In these cases, the parasite 
drug susceptibility before clinical treatment must 
be considered as a factor. Moreover, for a better 
understanding of the response to drugs, the local 
strains should be characterized genetically and 
biologically, as completed in this study (Luna KP, 
Jaramillo CL, Rueda CM, Hernández IP, Zorro 
MM, Angulo VM, et al. Biological and genetic 
characteristics of Trypanosoma cruzi isolates 
from an endemic area of Santander, Colombia. 
Bol Malariol Sal Amb. 2007;47 (Supl 1):139-40).
Many authors have explored possible links 
between the phylogenetic diversity of T. cruzi 
and biological properties (24,35-38). Correlations 
between the susceptibility to benznidazole and 
genetic groups of T. cruzi have been described 
(24,38). However, in the current study, no 
significant differences were observed in the drug 
susceptibility in vitro between T. cruzi I and T. 
cruzi II strains (figure 1). This is in agreement 
with Villareal et al. (2004) (39), although due to 
the low number of strains analyzed in the current 
work, the results obtained must be considered 
as preliminary data.
In conclusion, the current in vitro study described 
the susceptibility to miltefosine, nifurtimox and 
benznidazole of T. cruzi strains isolated from 
humans and vectors in the same transmission 
area of Chagas disease in Colombia. Miltefosine 
showed greater activity than the used reference 
drugs and no differences in the susceptibility 
according to host origin were observed. These 
were considered promising results. Further 
investigation with these strains in murine models 
of experimental Chagas disease will be necessary 
to establish the potential of miltefosine for the 
treatment of human Chagas disease before 
undertaking clinical studies.
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